RT Journal Article
SR Electronic
T1 Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group
JF British Journal of Ophthalmology
JO Br J Ophthalmol
FD BMJ Publishing Group Ltd.
SP 1605
OP 1610
DO 10.1136/bjophthalmol-2015-307950
VO 100
IS 12
A1 J Fernando Arevalo
A1 Andres F Lasave
A1 Lihteh Wu
A1 Dhariana Acon
A1 Michel E Farah
A1 Roberto Gallego-Pinazo
A1 Arturo A Alezzandrini
A1 Veronica Fortuna
A1 Hugo Quiroz-Mercado
A1 Guillermo Salcedo-Villanueva
A1 Mauricio Maia
A1 Martin Serrano
A1 Sergio Rojas
YR 2016
UL http://bjo.bmj.com/content/100/12/1605.abstract
AB Background/aims To report the long-term anatomical and functional outcomes of patients with centre-involved diabetic macular oedema (DME) treated with intravitreal bevacizumab (IVB).Methods Retrospective case series. Patients diagnosed with centre-involved DME that were treated with at least one injection of 1.25 mg IVB and had a minimum follow-up of 60 months. Patients underwent measurement of best-corrected visual acuity (BCVA), ophthalmoscopy, optical coherence tomography and fluorescein angiography at baseline, 6-month, 12-month, 24-month, 36-month, 48-month and 60-month visits. The paired samples t test was used to compare the central macular thickness (CMT) and BCVA with baseline values. Statistical significance was indicated by p<0.05.Results Two hundred and one consecutive patients (296 eyes) were included. The mean number of IVB injections per eye was 8.4±7.1 (range: 1–47 injections). At 5 years, the BCVA remained stable at 20/100 (logarithm of the minimum angle of resolution=0.7±0.4). Eighty-six (29%) eyes improved ≥2 lines of BCVA, 129 (43.6%) eyes remained stable and 81 (27.4%) eyes lost ≥2 lines of BCVA at 60 months. Mean CMT decreased from 403.5±142.2 μm at baseline to 313.7±117.7 μm over 5 years follow-up (p≤0.0001).Conclusions The early visual gains due to IVB were not maintained 5 years after treatment.